COSTA MESA, Calif., Dec. 5, 2013 /PRWeb/ — WCCT Global, a full service contract research organization headquartered in Southern California announced today that CEO Dr. Kenneth Kim will be presenting at the 2013 Up-to-date Topics in Global Clinical Trials Conference in Korea on December 11th. The event will be held at the Hotel Shilla in Seoul, Korea. Dr. Kim is a well-recognized expert in the area of global clinical development and his company WCCT Global is currently one of the leading full service CROs in the industry. WCCT Global is implementing fresh new ideas, and trends in: remote risk based monitoring, patient recruitment, and simultaneous vs. sequential global development will be among the topics covered. Dr. Kim stated, “I am pleased to be able to present where the clinical development industry is headed. With the use of technology and new clinical ideology, clinical research is becoming much more effective and leading to more efficient testing periods for new therapies.”

As global clinical trials development quickly evolves in areas including: regulatory, biometric, and clinical research. Staying informed with the latest methods of operation is vital to success in the industry. This conference will shed light on the potential of making global drug development more efficient, effective, and either cost neutral or less expensive than the previous traditional ways of research.

Since being founded, WCCT Global has been on the forefront of setting new trends for clinical development, and will continue its efforts towards conducting global clinical trials in the future. One way that WCCT Global works towards this goal is conducting ethnobridging trials, in which patients of multiple ethnic backgrounds are incorporated into the study to determine how drugs affect those who are from different geographic regions. These studies oftentimes present valuable information that would have had to be found in a separate trial, thus saving sponsors time and money in the drug development process, potentially bringing their drug closer to market.